
Inventor: Lautt, et al.
Docket No.: 14233.0017USWO
Title: USE OF GLUTATHIONE SYNTHESIS STIMULATING COMPOUNDS IN
REDUCING INSULIN RESISTANCE
Attorney Name: Douglas P. Mueller
Phone No.: (612) 371-5237
Sheet 1 of 5

Γ/CA03/00079

1/5

Figure 1



WO 03/061639

Inventor: Lautt, et al.

Docket No.: 14233.0017USWO


Title: USE OF GLUTATHIONE SYNTHESIS STIMULATING COMPOUNDS IN

2/5

REDUCING INSULIN RESISTANCE Attorney Name: Douglas P. Mueller Phone No.: (612) 371-5237

Sheet 2 of 5

CA03/00079




the RIST Index from 260.2 ± 15.6 mg glucose /kg to 121.2 \pm 12.8 mg glucose /kg (52.3 \pm 5.8% inhibition). SIN-1(5mg/kg, ipv) restores insulin response with a Control Group (n=6): L-NAME (1mg/kg, ipv) reduces 258.1 ±18.5 mg glucose /kg. RIST index of

Inventor: Lautt, et al.
Docket No.: 14233.0017USWO
Title: USE OF GLUTATHIONE SYNTHESIS STIMULATING COMPOUNDS IN
PEDILIPING INSUL BLUESESTANCE

WO 03/061639

REDUCING INSULIN RESISTANCE Attorney Name: Douglas P. Mueller Phone No.: (612) 371-5237 Sheet 3 of 5 PCT/CA03/00079

3/5



BSO Group (n=5). The control RIST index was 158.4±12.2 mg glucose /kg. Intraportal administration of L-NAME(1mg/kg) reduced significantly the RIST Index to 109.8±9.1mg glucose /kg.lpv administration of SIN-1 did not reverse the RIST Index to control values. *= p<0.05; ns= non significant

WO 03/061639

Insulin Action

Inventor: Lautt, et al.

Docket No.: 14233.0017USWO

Docket No.: 14233.001705WO Title: USE OF GLUTATHIONE SYNTHESIS STIMULATING COMPOUNDS IN

REDUCING INSULIN RESISTANCE Attorney Name: Douglas P. Mueller

Phone No.: (612) 371-5237 Sheet 4 of 5 CT/CA03/00079

4/5

HISS-dependent and HISS-independent components of insulin action in BSO and control groups. HISS-independent components are not different in both groups. HISS is significantly reduced in BSO group 138.9 ± 22.8 (49.3 ±8.56 mg glucose /kg) compared to control group decrease of corresponding mg glucose /kg) action. **=p<0.01 WO 03/061639


Inventor: Lautt, et al. Docket No.: 14233.0017USWO

Title: USE OF GLUTATHIONE SYNTHESIS STIMULATING COMPOUNDS IN

5/5

REDUCING INSULIN RESISTANCE Attorney Name: Douglas P. Mueller Phone No.: (612) 371-5237

Sheet 5 of 5



Hepatic glutathione content in BSO (n=5) and control (n=6) groups. In control group hepatic GSH content was significantly higher (5.66 \pm 0.1umol/g fresh liver) than in BSO group (2.96 \pm 0.4umol/g fresh liver). Hepatic GSH content was decreased by 48.3 \pm 6.9% in BSO group. ***=p<0.001